Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Xechem International -- Ignore unavailable to you. Want to Upgrade?

To: GatewayStocks who wrote (9)	2/28/2006 9:27:23 PM
From: GatewayStocks	Respond to of 75

With the Brytsol-Myers suit out of the way they can go forward with its paclitaxel drug?...... a generic equivalent of Bristol's cancer drug, TAXOL(R). Xechem International, Inc. is engaged primarily in applying its proprietary extraction, isolation and purification technology to the production and manufacture of paclitaxel. Paclitaxel is an anticancer compound used for the treatment of ovarian, breast, small cell lung cancers and AIDS related Kaposi sarcomas. The Company has successfully isolated pure paclitaxel and has received a process patent on this technology. The Company has submitted to the FDA a Drug Master File for the facility and the bulk paclitaxel product. The Company has been issued five U.S. patents on paclitaxel and its second generation analogs from the U.S. Patent and Trademark Office and over thirty-four international patents are pending.